|Calculated MW||39062 Da|
|Other Names||HLA class I histocompatibility antigen, alpha chain F, CDA12, HLA F antigen, Leukocyte antigen F, MHC class I antigen F, HLA-F, HLA-5.4, HLAF|
|Target/Specificity||This HLA-F antibody is generated from a mouse immunized with a recombinate protein from the human region of human HLA-F.|
|Storage||Maintain refrigerated at 2-8°C for up to 2 weeks. For long term storage store at -20°C in small aliquots to prevent freeze-thaw cycles.|
|Precautions||HLA-F Antibody is for research use only and not for use in diagnostic or therapeutic procedures.|
|Function||Non-classical major histocompatibility class Ib molecule postulated to play a role in immune surveillance, immune tolerance and inflammation. Functions in two forms, as a heterotrimeric complex with B2M/beta-2 microglobulin and a peptide (peptide-bound HLA-F-B2M) and as an open conformer (OC) devoid of peptide and B2M (peptide-free OC). In complex with B2M, presents non-canonical self-peptides carrying post-translational modifications, particularly phosphorylated self-peptides. Peptide-bound HLA-F-B2M acts as a ligand for LILRB1 inhibitory receptor, a major player in maternal-fetal tolerance. Peptide-free OC acts as a ligand for KIR3DS1 and KIR3DL2 receptors (PubMed:28636952). Upon interaction with activating KIR3DS1 receptor on NK cells, triggers NK cell degranulation and anti-viral cytokine production (PubMed:27455421). Through interaction with KIR3DL2 receptor, inhibits NK and T cell effector functions (PubMed:24018270). May interact with other MHC class I OCs to cross-present exogenous viral, tumor or minor histompatibility antigens to cytotoxic CD8+ T cells, triggering effector and memory responses (PubMed:23851683). May play a role in inflammatory responses in the peripheral nervous system. Through interaction with KIR3DL2, may protect motor neurons from astrocyte-induced toxicity (PubMed:26928464).|
|Cellular Location||Cell membrane; Single- pass type I membrane protein. Early endosome membrane. Lysosome membrane. Note=For cross-presentation transits from the cell surface through endosomal pathway to lysosomes, where the peptide is generated from internalized exogenous antigen.|
|Tissue Location||Expressed in resting B cells (at protein level). Expressed in secondary lymphoid organs rich in B and T cells such as the tonsils, spleen, and thymus (at protein level) (PubMed:10605026, PubMed:11169396). Expressed in the endothelial cells of the tonsils (PubMed:11169396). Expressed on activated lymphoid cells including B cells, NK cells, CD4+ T cells and memory T cells (at protein level) (PubMed:27455421, PubMed:20865824). Expressed in motor neurons of spinal cord (PubMed:26928464).|
Provided below are standard protocols that you may find useful for product applications.
Involved in the presentation of foreign antigens to the immune system.
Geraghty D.E.,et al.J. Exp. Med. 171:1-18(1990).
Lury D.,et al.Int. Immunol. 2:531-537(1990).
Hampe A.,et al.DNA Seq. 10:263-299(1999).
He X.,et al.Tissue Antigens 63:181-183(2004).
Pyo C.W.,et al.Immunogenetics 58:241-251(2006).